Brookline Capital Management Weighs in on Moderna, Inc.’s FY2026 Earnings (NASDAQ:MRNA)

Moderna, Inc. (NASDAQ:MRNA) – Equities research analysts at Brookline Capital Management lifted their FY2026 EPS estimates for shares of Moderna in a report issued on Thursday, May 2nd. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings per share of $12.97 for the year, up from their prior forecast of $12.50. The consensus estimate for Moderna’s current full-year earnings is ($7.47) per share. Brookline Capital Management also issued estimates for Moderna’s FY2027 earnings at $17.75 EPS and FY2028 earnings at $39.59 EPS.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. During the same quarter last year, the firm posted $0.19 EPS. The company’s quarterly revenue was down 91.0% on a year-over-year basis.

A number of other brokerages also recently commented on MRNA. Jefferies Financial Group reissued a “buy” rating and issued a $125.00 price objective on shares of Moderna in a research report on Tuesday, April 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Thursday. HSBC reaffirmed a “reduce” rating and set a $86.00 target price (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Oppenheimer lifted their target price on shares of Moderna from $142.00 to $163.00 and gave the stock an “outperform” rating in a report on Friday. Finally, Royal Bank of Canada lifted their target price on shares of Moderna from $125.00 to $135.00 and gave the stock an “outperform” rating in a report on Friday. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Moderna presently has an average rating of “Hold” and an average target price of $129.55.

Moderna Stock Performance

Shares of MRNA opened at $125.00 on Monday. The firm has a 50-day moving average of $105.05 and a 200-day moving average of $94.48. Moderna has a one year low of $62.55 and a one year high of $142.79. The company has a market cap of $47.86 billion, a PE ratio of -7.98 and a beta of 1.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.36.

Hedge Funds Weigh In On Moderna

Hedge funds and other institutional investors have recently made changes to their positions in the company. Ogorek Anthony Joseph NY ADV acquired a new position in shares of Moderna in the 4th quarter valued at approximately $27,000. Arlington Trust Co LLC raised its position in shares of Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after buying an additional 290 shares in the last quarter. Westside Investment Management Inc. acquired a new position in shares of Moderna in the 1st quarter valued at approximately $32,000. Rise Advisors LLC raised its position in shares of Moderna by 953.3% in the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after buying an additional 286 shares in the last quarter. Finally, UMB Bank n.a. raised its position in shares of Moderna by 121.8% in the 1st quarter. UMB Bank n.a. now owns 366 shares of the company’s stock valued at $39,000 after buying an additional 201 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Moderna news, insider Shannon Thyme Klinger sold 544 shares of Moderna stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $99.05, for a total value of $53,883.20. Following the completion of the sale, the insider now owns 9,267 shares in the company, valued at approximately $917,896.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO James M. Mock sold 647 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the transaction, the chief financial officer now directly owns 4,300 shares in the company, valued at approximately $406,651. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Shannon Thyme Klinger sold 544 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $99.05, for a total transaction of $53,883.20. Following the completion of the transaction, the insider now owns 9,267 shares of the company’s stock, valued at $917,896.35. The disclosure for this sale can be found here. Insiders sold 139,954 shares of company stock worth $14,822,576 in the last quarter. 15.70% of the stock is currently owned by corporate insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.